Theratechnologies (TSE:TH) Stock Passes Above 50-Day Moving Average - Should You Sell?

Key Points

• Theratechnologies Inc. stock has recently surpassed its 50-day moving average of C$4.14, trading as high as C$4.51; the last trading price was C$4.50.
• Jones Trading downgraded the stock from a "strong-buy" to a "hold" rating, with the average rating currently being "Buy" based on analyst evaluations.
• The company has a market capitalization of C$143.57 million and operates primarily in the specialty pharmaceutical sector, focusing on HIV treatment.

Theratechnologies Inc. (TSE:TH - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$4.14 and traded as high as C$4.51. Theratechnologies shares last traded at C$4.50, with a volume of 11,975 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Theratechnologies presently has an average rating of "Buy".

Theratechnologies Stock Down 0.2%

The firm has a market capitalization of C$143.57 million, a price-to-earnings ratio of -50.94, a P/E/G ratio of -8.50 and a beta of 1.73. The business has a 50 day simple moving average of C$4.14 and a 200-day simple moving average of C$3.38. The company has a debt-to-equity ratio of -293.92, a quick ratio of 0.64 and a current ratio of 1.08.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.